Federal Marijuana Rescheduling: What's Actually Changed in 2026

A clear look at recent federal action on cannabis — and what it means in practice.

Federal cannabis policy has been moving, and the headlines haven't always captured it accurately. Here's a straightforward summary of where things actually stand in 2026, particularly for anyone whose job, federal employment prospects, or security clearance could be affected.

What Has Happened

In December 2025, President Trump signed an executive order titled “Increasing Medical Marijuana and Cannabidiol Research,” which directed the Attorney General to move forward with the process of rescheduling marijuana to Schedule III of the Controlled Substances Act. Following that, in April 2026, the Department of Justice issued an order moving two specific, narrow categories of marijuana — FDA-approved marijuana products and state-licensed medical marijuana — to Schedule III. Recreational marijuana remains in Schedule I. The DOJ also set an expedited administrative hearing process, beginning in mid-2026, to consider broader rescheduling.

On paper, that's a meaningful shift. Schedule III is the category for substances with an accepted medical use, placing certain medical cannabis products alongside drugs that can be used legally under a doctor's supervision.

What Has Not Changed

This is the part that matters most, and where a lot of online commentary has been misleading. For federal employees, contractors, and security clearance holders, the practical rules have not changed:

• Federal drug testing panels are unchanged. Marijuana remains on the panel, and authorized testing requirements have not been altered.
• The standards used to evaluate security clearances — including the adjudicative guideline on drug involvement and the controlling 2021 guidance on marijuana — remain in effect as written.
• Rescheduling is not retroactive. Marijuana use that occurred while it was federally illegal can still be treated as a security concern, because the issue is partly about willingness to follow federal law at the time.
• Individual agencies and federal contractors may still have their own policies prohibiting cannabis use, regardless of its federal schedule.

In short: a Schedule III designation reflects shifting attitudes and an expansion of accepted medical use, but it does not give federal workers or clearance holders a green light to use cannabis. Rulemaking of this kind is slow, can be subject to legal challenge, and the agency-level guidance that governs day-to-day decisions has not yet caught up.

The Bigger Picture

Federal policy has loosened gradually over recent years — guidance issued in 2021 and 2022 already advised that past marijuana use alone should not automatically disqualify someone from a federal job or clearance. The 2025–26 rescheduling steps continue that direction of travel. But the gap between evolving policy and the rules people are actually held to remains real, and anyone in a federally sensitive role should treat cannabis decisions with caution and get advice specific to their situation.

This article is for general information only and is not legal or medical advice. Federal drug policy, security clearance rules, and agency-specific guidance can change. Anyone facing a decision about cannabis use in connection with federal employment or a security clearance should consult a qualified attorney about their specific circumstances.

Last reviewed: May 2026.